China (Mainland)
Premiumsupplier
API Antibiotics Beta-Lactamase Inhibitor Meropenem CAS 96036-03-2 CAS NO.96036-03-2
- Min.Order: 100 Gram
- Payment Terms: L/C,T/T,
- Product Details
Keywords
- CAS 96036-03-2
- Meropenem
- C17H25N3O5S
Quick Details
- ProName: API Antibiotics Beta-Lactamase Inhibit...
- CasNo: 96036-03-2
- Molecular Formula: C17H25N3O5S
- Appearance: White to yellowish crystalline powder
- Application: Meropenem is a new carbapenem antibiot...
- DeliveryTime: as customers request
- PackAge: 1kg/Aluminum Foil Bag 25kg/Fiber Drum
- Port: any port in China
- ProductionCapacity: 1000 Kilogram/Year
- Purity: >99%
- Storage: Cool Dry Place
- Transportation: by sea or by air
- LimitNum: 100 Gram
Superiority
| 1)Quick Response Within 12 hours; |
| 2)Quality Guarantee: All products are strictly tested by our QC, confirmed by QA and approved by third party lab in China, USA, Canada, Germany, UK, Italy, France etc. |
| 3) OEM/ODM Available; |
| 4) Reasonable & Competitive Price; |
| 5) Fast Delivery: Samples from stock; bulk products within 7 days; |
| 6) Professional Documents for Your Clearance; |
| 7) Economic Freight Save Your Cost; |
| 8) All your money be refund immediately if quality issue happens. |
Details
Introduction:
Meropenem is a new carbapenem antibiotic introduced to market for the i.v. treatment of a wide variety of hospital infections such as lower respiratory tract, urinary tract, intraabdominal, gynecological and polymicrobial infections. Meropenem has a broad spectrum of antibacterial activity against most clinically important Gram-positive and Gramnegative aerobic and anaerobic bacteria with especially high potency against multiresistant Enterobacteriaceae and Pseudornonas aeruginosa. Compared with imipenem, the only other available carbapenem antibiotic, meropenem has the advantage of being dehydropeptidase 1 (DHP-1) stable and therefore does not need to be administered in conjunction with the DHP-1 inhibitor cilastatin. Meropenem is also being evaluated for treatment of resistant pseudomonal infections in cystic fibrosis patients.
| Product Name |
Meropenem with Sodium Carbonate |
||
| Shelf Life | 2 years | ||
|
ANALYSIS TEST |
SPECIFICATIONS |
RESULTS |
|
|
Appearance |
White to yellowish crystalline powder |
Conformed |
|
|
Identification |
positive |
Conformed |
|
| PH | 7.3~8.3 | 7.9 | |
| Loss on drying | 9.0%~12.0% | 10.1% | |
| Colour of solution | ≤Y5# orK5# of reference solution | ＜K1# | |
| Clarity of solution | ≤05# of reference suspension | ＜0.5# | |
| Visible matter | Comply with the requirement | complies | |
| Limit of Acetone | ≤0.05% | 0.01% | |
| Bulk density | Informative | 043g/cm3 | |
|
Related substance On dry basis |
PRT(0.45) | ≤0.80% | 0.02% |
| PRT(1.90) | ≤0.60% | ND | |
| Particulate Matter | ≥10um | ≤4000 per container | 126 per container |
| ≥25um | ≤400 per container | 0 per container | |
| Uniformity of dosage units | Meets the requirements | Conformed | |
| Bacterial endotoxinsunder | ≤0.125EU/mg | Conformed | |
| Sterility | Meets the requirements | Conformed | |
|
Assay(C17H25N3O5S) on anhydrous basis |
≥78.0% | 82.3% | |